



Published in final edited form as:

Nat Genet. 2021 July ; 53(7): 1088–1096. doi:10.1038/s41588-021-00874-3.

Radiotherapy is associated with a deletion signature that contributes to poor outcomes in cancer patients

Emre Kocakavuk^{1,2,3}, Kevin J. Anderson¹, Frederick S. Varn¹, Kevin C. Johnson¹, Samirkumar B. Amin¹, Erik. P. Sulman⁴, Martijn P. Lolkema⁵, Floris P. Barthel^{*,¥,1,6}, Roel G.W. Verhaak^{*,1}

¹The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA

²DKFZ Division of Translational Neurooncology at the West German Cancer Center, German Cancer Consortium Partner Site, University Hospital Essen, Essen, Germany

³Department of Neurosurgery, University Hospital Essen, Essen, Germany

⁴NYU Langone Health, New York, NY, USA

⁵Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

⁶Department of Pathology, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Abstract

Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but we have limited understanding of its genomic impact. We analyzed mutational spectra following radiotherapy in 190 paired primary and recurrent gliomas from the Glioma Longitudinal Analysis (GLASS) Consortium and 3,693 post-treatment metastatic tumors from the Hartwig Medical Foundation. We identified radiotherapy-associated significant increases in the burden of small deletions (1–20 bp) and large deletions (20+ bp to chromosome-arm length). Small deletions were characterized by a larger span size, lacking breakpoint microhomology and were genomically more dispersed when compared to pre-existing deletions and deletions in non-irradiated tumors. Mutational signature analysis implicated c-NHEJ-mediated DNA damage repair and APOBEC-mutagenesis following radiotherapy. A high radiation-associated deletion burden was associated with worse clinical outcomes, suggesting that effective repair of radiation-induced DNA damage is detrimental to

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence: fbarthel@tgen.org, roel.verhaak@jax.org.

[¥]Present address: Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.

^{*}Co-senior authors

Author contributions

E.K., F.P.B. and R.G.W.V. designed the project. Data processing and analysis was performed by E.K. and F.B.P., data visualization was performed by E.K., E.K., K.J.A., F.S.V., K.C.J., S.B.A., F.B.P. and R.G.W.V. participated in the design of analyses and interpretation of results. M.P.L. provided clinical data. E.K., F.B.P. and R.G.W.V. wrote the manuscript. All co-authors including M.P.L. and E.P.S. discussed the results and commented on the manuscript.

Competing Interests

R.G.W.V. is a co-founder of Boundless Bio, Inc., which was not involved in the research presented here. R.G.W.V. is a member of Scientific Advisory Board of the Hartwig Medical Foundation. F.P.B. has performed consulting for Bristol Myers Squibb. R.G.W.V., E.K., K.J.A., and F.P.B. are listed as inventors on a patent application filed by The Jackson Laboratory, related to the findings described here. The remaining authors declare no competing interests.

patient survival. These results may be leveraged to predict sensitivity to radiation therapy in recurrent cancer.

INTRODUCTION

Radiation therapy or radiotherapy (RT) is used in the clinical management of more than half of all cancer patients^{1,2}. Ionizing radiation kills cells by inducing DNA damage such as double-strand breaks (DSBs), leading to cell death if left unrepaired or repaired in a manner that inhibits subsequent replication. DNA repair pathways are activated in response to DSBs, and these pathways include the error-free homologous recombination (HR) pathway and three error-prone pathways: classical non-homologous end joining (c-NHEJ), alternative end joining (a-EJ) or single strand annealing (SSA)³. In contrast to HR, c-NHEJ, a-EJ and SSA require different lengths of microhomologous sequences present on exposed DNA ends. Whereas c-NHEJ requires no microhomologies, a-EJ uses 2–20 bp length of microhomology (also called microhomology-mediated end joining, MMEJ) and SSA uses >20 bp of (micro-)homology. These repair processes may cause changes in the post-treatment cancer genome that can be detected through sequencing. The identification of therapy-associated mutations may imply an effect of therapy on the tumor and can aid in characterization of therapy-resistance mechanisms. A well-known example of such a process is hypermutation following treatment with DNA-alkylating agents, observed across cancers⁴ and in particular following temozolomide (TMZ) chemotherapy of gliomas^{5,6}. Similarly, an increased burden of small deletions has been observed in radiation-induced malignancies⁷. Despite these advancements, the mutational footprints of palliative and curative radiation in sporadic tumors are not well understood.

To address this gap in knowledge we analyzed pre- and post-treatment datasets from the Glioma Longitudinal Analysis (GLASS) cohort as well as post-treatment metastatic tumor datasets from the Hartwig Medical Foundation (HMF)^{5,8,9}. We identified a significant increase of small 5–15bp deletions, large deletions and inversions (>20 bp) in response to ionizing radiation, which we genomically characterized. Finally, we observed that the identified signatures were associated with worse clinical outcomes.

RESULTS

Radiotherapy drives small deletion burden

Radiotherapy and temozolomide are the post-surgical standard of care for glioma patients¹⁰. We assessed the impact of RT and/or TMZ on the somatic mutation burden, including somatic single nucleotide variants (sSNVs) and small insertions/deletions (indels, length of 1 to 20bp), in matched pre- and post-treatment glioma samples ($n = 190$ patients). Of these, 119 (63%) patients received RT and TMZ, 19 (10%) received RT alone, 13 (7%) received only TMZ, and 16 (8%) received neither RT nor TMZ. For 23/190 (12%) cases, TMZ annotation was lacking with 18 of these having received RT. For each patient, we separated mutations into pre- (present in the primary tumor) and post-treatment (acquired, only present in the recurrent tumor). We then calculated the mutation burden (average mutation frequency per megabase (Mb)) of post-treatment mutations. A median of 0.68 new small deletions/Mb

were acquired in recurrent RT-treated glioma which was significantly higher than the median of 0.19 new small deletions/Mb acquired in recurrent RT-naïve gliomas (Fig. 1a, $P = 5.1 \times 10^{-3}$, Mann-Whitney U test), and significantly higher than the small deletion burden detected at diagnosis (Fig. 1b). RT was not associated with a significant increase in sSNV burden (Extended Data Fig. 1a, $P = 4.7 \times 10^{-1}$, Mann-Whitney U test) or small insertion burden (Extended Data Fig. 1a, $P = 6.7 \times 10^{-1}$, Mann-Whitney U test). The small deletion increase was particularly pronounced in gliomas marked by the presence of mutations in *IDH1*, a clinically relevant subtype¹¹ predominantly consisting of grade II and III gliomas (Extended Data Fig. 1b, $P = 1.4 \times 10^{-2}$, Mann-Whitney U test). The number of RT-naïve recurrent cases among *IDH* wild-type glioma was too small to test for differences ($n = 2$, vs $n = 107$ RT-treated cases). To ensure that these changes were not due to TMZ-associated hypermutation (>10 mut/Mb at recurrence)⁵, we stratified the cohort by hypermutation status. Hypermutation associated with small deletion increase independent of RT-treatment, whereas amongst non-hypermutators only RT-treated patients showed a significant increase in small deletions (Fig. 1b, $P = 5.0 \times 10^{-11}$, paired Wilcoxon signed-rank test). To evaluate the independence of this finding from potential confounders, we fitted a multivariable log-linear regression model that included TMZ-treatment, glioma molecular subtype, time interval between surgeries and hypermutation. RT was independently associated with an increase in small deletions (Fig. 1c, $P = 3 \times 10^{-3}$, t-test), directly attributing the observed small deletion increase to RT-treatment. Acquired small deletions were not more clonal/subclonal (Extended Data Fig. 1c, hypermutant: $P = 9.3 \times 10^{-1}$, non-hypermutant: $P = 8.7 \times 10^{-1}$, Mann-Whitney U test). Comparing the pre-treatment mutation burden and aneuploidy scores between high- and low- post-treatment deletion burden tumors revealed no significant differences, suggesting that these pre-RT tumor genomic characteristics are not predictive of RT-induced small deletion acquisition.

Importantly, 30% (41/136) of non-hypermutant samples gained >1 del/Mb following radiotherapy, compared to 7% (2/27) of RT-naïve non-hypermutators ($P = 1.6 \times 10^{-2}$, Fisher's exact test). The association between RT-treatment and mutational burden was significant for small deletions but not for insertions and sSNVs. Conversely, TMZ-associated hypermutation was correlated with a significant increase in the burden of all types of mutations (Extended Data Fig. 1d).

Following these observations, we hypothesized that radiotherapy may have similar effects in other tumor types. We evaluated whole-genome sequencing-derived mutational profiles from 3693 metastatic tumors with complete treatment annotation (Extended Data Fig. 1e), available via the Hartwig Medical Foundation (HMF)⁸. We separated tumors by site of origin and compared the small deletion burden between RT-treated and RT-naïve tumors (Fig. 1d). RT-treated tumors were further stratified depending on whether the treatment intent was curative (RT+cur, $n = 739$) or palliative (RT+pal, $n = 689$), which differ in cumulative radiation dosage¹². While this analysis was restricted to single time-point mutational profiles, we observed a significantly higher small deletion burden in RT-treated patients across multiple tumor types, including bone/soft tissue (RT+cur: median 0.15 del/Mb, RT-: median 0.08 del/Mb, $P = 6.2 \times 10^{-4}$, Kruskal-Wallis test), lung (RT+cur: median 0.56 del/Mb, RT-: median 0.43 del/Mb, $P = 3.4 \times 10^{-3}$, Kruskal-Wallis test), and breast (RT+cur: median 0.18 del/Mb, RT-: median 0.12 del/Mb, $P = 1.2 \times 10^{-4}$, Kruskal-Wallis test)

cancers (Fig. 1d). The observed patterns were present in both non-small cell and small cell lung cancer but were restricted to ER-positive breast cancer subtypes (Extended Data Fig. 1f). Tumors receiving palliative RT frequently presented an intermediate state in between the RT- and RT+cur cohorts, suggesting an association between acquired small deletion burden and RT dose.

DNA repair deficiency associates with increased mutational load⁴. We compared the small deletion burden between HMF tumors with and without microsatellite instability (MSI) or homologous recombination deficiency (HRD)¹³. Notably, HRD+ and particularly MSI+ tumors harbored significantly more small deletions compared to HRD-/MSI- samples (Extended Data Fig. 1g, $P < 2.2\text{e-}16$, Kruskal-Wallis test). RT-treatment was associated with a small deletion burden increase in HRD-/MSI- (Extended Data Fig. 1g, $P = 6.0\text{e-}08$, Mann-Whitney U test) and HRD+ tumors ($P = 3.5\text{e-}02$), but not in MSI+ tumors ($P = 7.1\text{e-}01$). To account for the possibility that HRD and MSI confounded the association between RT-treatment and the small deletion burden, we have included HRD and MSI status into a multivariable log-linear regression analysis and found that the association between RT-treatment and small deletion burden is independent of HRD/MSI status (Extended Data Fig. 1h).

Next, we assessed whether the small deletion burden was associated with mutations in selected genes (*ATM*, *ATR*, *CHEK1*, *CHEK2*, *PARP1*, *PRKDC*, *TP53* and *WEE1*) involved in the DNA damage response (DDR). This analysis indicated that DDR mutations in these genes were universally associated with a significantly higher small deletion burden. We used log-linear regression to adjust for potential confounding variables, including age, tumor type, DNA damage repair background, DRR gene mutations and various cytotoxic treatment regimens (e.g. taxane, platinum, anthracyclines, alkylating agents) that have been previously associated with increased mutation burdens¹⁴. Results from this analysis confirmed a robust association with an increased small deletion burden for both palliative and curative radiotherapy (Extended Data Fig. 1h, RT+cur vs. RT-naïve: odds ratio = 1.25, $P < 1\text{e-}03$, t-test).

To verify the causal association between RT and acquired small deletions, we re-analyzed whole-genome sequencing data from 324 human-induced pluripotent stem cells (iPSCs) exposed to various carcinogens, including two iPSCs treated with ionizing radiation¹⁵. Small deletion burden was significantly higher in the RT-treated iPSCs compared to controls (Extended Data Fig. 1i, $P = 2.0\text{e-}02$, Mann-Whitney U test). In contrast, there was no significant difference in small insertion burden ($P = 1.8\text{e-}01$). Strikingly, the ionizing radiation group showed the highest median burden of small deletions across all treatment modalities, further substantiating our results (Extended Data Fig. 1k).

RT-associated deletions harbor a specific genomic signature

Characteristics of RT-associated small deletions, such as length distribution and breakpoint microhomology, may provide insights into their etiology. We explored such features in GLASS *IDH* mutant gliomas (RT+, n=49; RT-, n=32) as only two GLASS *IDH* wild-type gliomas were not RT-treated (vs. 107 RT-treated). Small deletions in RT-treated recurrent tumor samples showed increased deletion lengths (Fig. 2a, left, RT+: $P = 1.5\text{e-}04$; RT-: $P =$

3.5e-01, paired Wilcoxon signed-rank test), which was even more pronounced in acquired deletions (Extended Data Fig. 2a, $P = 1.3\text{e-}04$, Mann-Whitney U test), supporting the idea that RT results in longer deletions (Fig. 2a, left). Moreover, the size distribution of RT-associated deletions shifted towards deletions of length ~5–15bp (Fig. 2a, right).

Comparing RT-treated and RT-naïve metastatic tumor samples from the single time-point HMF dataset confirmed larger deletions in palliative and curative RT-treated tumors (Fig. 2b, Extended Data Fig. 2b), and a shift in deletion span from 1–4bp towards 5–15bp deletions (Fig. 2b). Deletion length was larger following curative compared to palliative RT-treatment, further substantiating a dose and exposure association. Taken together, RT drives a burden of small deletions with distinct characteristics.

B-DNA is the common right-handed, double helical formation of DNA. Non-canonical non-B-DNA structures and fragile repeat-rich DNA may be more prone to acquiring mutations¹⁶, which may include RT-induced deletions. We compared the distribution of small deletions across these genomic features against a random background distribution. In the IDH-mutant GLASS cohort, deletions following RT showed less variability and higher similarity to the random background distribution compared to non-RT-induced deletions, and larger distances to non-B DNA features (Fig. 2c, right, Extended Data Fig. 2c). The lack of or reduced association between RT-associated deletions and the analyzed genomic features, such as repeats and G-quadruplex motifs, suggests that RT-associated small deletions occur in a stochastic manner, independent from the intrinsic mutagenicity of the fragile genome regions analyzed.

We assessed whether RT-associated small deletions showed enrichment in driver genes. We computed the covariate-adjusted normalized ratio between non-synonymous and synonymous mutations (dN/dS), in order to identify selection of mutations at the level of individual genes and separately for GLASS pre- and post-treatment fractions (Extended Data Fig. 2d)¹⁷. We did not find evidence for significant selection for any genes in the post-treatment fraction following radiation therapy. In the HMF set, where pre-treatment samples are unavailable, we could not perform this analysis. Our results in IDH-mutant glioma further support the notion that RT-associated deletions do not occur at particular genomic loci.

Small deletions can be the result of error-prone DSB-repair mechanisms such as c-NHEJ and a-EJ/MMEJ³. We characterized deletions based on size, microhomology and repeat content to investigate which mechanism is used for DSB-repair following RT (Fig. 2d, Extended Data Fig. 2e). Deletions without microhomology comprised the majority of deletions in the dataset (77%, Fig. 2d). However, in non-hypermutable gliomas receiving ionizing radiation we observed a significant increase in >1bp-deletions without microhomology (Fig. 2d, $P = 6.6\text{e-}05$, Paired Wilcoxon signed-rank test) and conversely a decrease in 1bp-deletions (Fig. 2d, $P = 6.5\text{e-}03$, Paired Wilcoxon signed-rank test). Comparison of RT-treated and RT-naïve metastatic tumors from the HMF dataset demonstrated comparable results (Extended Data Fig. 2f). These data suggest that c-NHEJ is the preferred pathway for repairing radiation-induced DNA damage.

Distinct mutational signatures associated with radiotherapy

Cancer cells accumulate somatic mutations through mechanisms that may leave distinct genomic scars, termed mutational signatures¹⁸. To determine the mutational processes of radiotherapy, we compared pre- and post-treatment mutations in the GLASS dataset to previously defined mutational signatures¹⁸. The comparison of signature contributions between post-recurrence mutations in RT-treated and RT-naïve *IDH* mutant glioma samples revealed a strong enrichment of indel signature 8 (ID8, Fig. 3, Extended Data Fig. 3d, RT+, mean contribution = 0.22, vs. RT-, mean contribution = 0.07, $P = 7.4 \times 10^{-5}$, $Q = 3.8 \times 10^{-3}$, Mann-Whitney U test and false discovery rate, respectively). In RT-treated but not RT-naïve patients comparing ID8 values before and after treatment resulted in significant increases in absolute (Extended Data Fig. 3e, $P = 4.5 \times 10^{-7}$, Paired Wilcoxon rank-signed test) and relative (Extended Data Fig. 3e, $P = 2.3 \times 10^{-3}$) ID8 contributions, respectively. ID8 is composed of ≥ 5 bp deletions without microhomology and has previously been linked to DSB repair by c-NHEJ, suggesting radiation-induced DSB repair via c-NHEJ¹⁸. As expected, hypermutation due to TMZ treatment in *IDH* mutant gliomas was associated with indel signature 2, which is reported to be elevated in mismatch repair deficient tumors (ID2, Fig. 3, Extended Data Fig. 3a–b)¹⁸.

A previous mutational signature analysis in the HMF dataset observed the strongest association between RT and ID6¹⁴. Confirming our findings in the GLASS cohort, we observed the strongest association with ID8 in the HMF dataset, and significant but less pronounced for ID6 (Fig. 3). Both absolute and relative ID8 values were significantly higher in RT-treated samples when compared to RT-naïve samples, and a significant association was observed in nine of twelve tumor types (Extended Data Fig. 3f). The comparison of HRD+ and HRD- samples associated HR-deficiency with ID6. ID6 comprises > 5 bp deletions with microhomology at breakpoints and is elevated in HR-defective breast cancers¹⁹. Analogous to TMZ-associated hypermutators in GLASS, MSI samples in HMF were enriched for indel signature 2 (ID2, Fig. 3).

To summarize, while MSI leads to an increased small deletion burden due to hypermutability from impaired DNA mismatch repair at microsatellites/homopolymers, DSBs due to HRD and RT are repaired via error-prone DSB-repair mechanisms. Our results implicate the a-EJ pathway that utilizes microhomologies at breakpoints in HR-deficient samples (signature ID6) and the c-NHEJ pathway which does not require breakpoint-microhomology in RT-treated samples (signature ID8).

We sought to identify single base substitution (SBS) signature associations in both datasets. We confirmed an enrichment of SBS11 in hypermutant *IDH* mutant glioma samples^{5,20}, an enrichment of signatures SBS44, SBS26, SBS21, SBS20 and SBS15 in MSI samples¹⁸ and enrichment of SBS3 and SBS8 in HRD cases^{18,19,21} along with a previously undescribed enrichment of SBS39 (Fig 3). In addition, in the GLASS cohort, RT-treatment was significantly associated with SBS13 and in the HMF cohort with SBS2 and SBS13. SBS2 and SBS13 are APOBEC signatures^{18,22}. APOBEC cytosine deaminases are involved in retrovirus and retrotransposon restriction, and the enrichment of APOBEC signatures in RT-treated samples in both datasets implicated APOBEC-mediated mutagenesis in RT-associated DSB-repair^{23–25}. Our results support the hypothesis that mutational signatures

are shaped by cycles of DNA damage and DNA repair²⁶. While radiotherapy causes DSBs that are repaired via c-NHEJ resulting in specific small deletions (ID8), APOBEC cytidine deaminases may be activated during the repair process leading to SBS2 and / or SBS13.

Radiotherapy associates with aneuploidy and larger deletions

We evaluated whether RT could be associated with other types of genomic variants. We detected large structural variants, including large deletions, duplications, inversions and translocations, in the longitudinal GLASS cohort. We observed an increase in large deletions (length > 20bp to chromosome arm length) post-therapy in RT-treated patients, compared to RT-naïve patients (Fig. 4a, $P = 3.2 \times 10^{-2}$, Fisher's exact test). We also found a statistically significant increase in inversions (Fig. 4a, $P = 2.1 \times 10^{-2}$) and no differences in translocations (Fig. 4a, $P = 1$) and duplications (Fig. 4a, $P = 7 \times 10^{-1}$). These associations remained significant after accounting for potentially confounding factors such as TMZ treatment and molecular subtype (Extended Data Fig. 4b). While radiation-induced secondary malignancies were reported to contain increased rates of inversions⁷, a concomitant increase in large deletions in association with RT has not been previously observed.

We next evaluated whether deletions at specific loci were associated with RT. In the IDH-mutant GLASS cohort, where *CDKN2A* loss at initial diagnosis is rare, acquired *CDKN2A* homozygous deletions occurred exclusively in RT-treated recurrences (Fig. 4b, 29% vs 0%, $P = 5.3 \times 10^{-4}$, Fisher's exact test)²⁷. This result nominated acquired *CDKN2A* homozygous loss as a potential biomarker for RT resistance among recurrent IDH-mutant gliomas, but not in IDH-wild type gliomas where *CDKN2A* homozygous deletion at diagnosis is common.

Ionizing radiation can promote mitotic chromosome segregation errors through non-disjunction events causing aneuploidy^{28–31}. We investigated the association between RT and aneuploidy, separating aneuploidy events into gains or losses of entire chromosomes, likely the result of segregation errors; and partial gains or losses, requiring additional DSBs (see Methods, Extended Data Fig. 4c). In the IDH-mutant GLASS cohort, we observed a significant association between RT and chromosome losses, but not for simple gains or complex events (Fig. 4c, Extended Data Fig. 4d), which was no longer significant after adjusting for covariates in a multivariable Poisson regression. Instead, this analysis highlighted a significant association between chromosome losses and *CDKN2A* deletions (Extended Data Fig. 4e), implicating that the increase in chromosome loss frequency following RT is specific to RT-associated acquired *CDKN2A* deletions. Using the HMF metastatic tumor cohort, we confirmed the association between *CDKN2A* homozygous deletions and chromosome losses (Fig. 4d, Extended Data Fig. 4f). In fact, both curative RT-treatment and *CDKN2A* homozygous deletions were independently associated with increased number of chromosomal losses in the HMF datasets (Fig. 4d, Extended Data Fig. 4f). However, testing for interactions between *CDKN2A* deletions and RT-treatment indicated a trend towards interaction between palliative/curative radiotherapy and *CDKN2A* deletions (Supplementary Table 1, $P = 9.75 \times 10^{-2}$ and $P = 4.92 \times 10^{-2}$, respectively, t-test). In summary, aneuploidy may not directly be associated with radiotherapy but through interactions with *CDKN2A* deletions, requiring further investigation.

RT-associated genomic changes are linked to poor survival

Finally, we wanted to ascertain whether the genomic effects of radiotherapy were relevant to patient outcomes. As expected, *CDKN2A* homozygous deletion at recurrence was significantly associated with worse overall survival in IDH-mutant glioma samples (Extended Data Fig. 5a, $P < 1e-04$, log-rank test)⁵. To test for a survival association of *CDKN2A* deletions amongst RT-treated patients in the HMF dataset we selected 958 samples that received RT and had sufficient survival information available from 11 tumor types (Extended Data Fig. 1e). Patients whose tumors harbored a *CDKN2A* homozygous deletions showed worse outcomes compared to patients with *CDKN2A* wild-type tumors (Extended Data Fig. 5b, left). Stratification of the cohort into tertiles based on genome-wide aneuploidy frequency demonstrated that low aneuploidy was linked to favorable outcomes and high aneuploidy was linked to poor outcomes (Extended Data Fig. 5b, middle). These results nominate acquired *CDKN2A* homozygous deletion as a biomarker of RT resistance after recurrence and support the clinical reassessment of *CDKN2A* status at recurrence for optimizing treatment strategies.

Independent of the poor prognostic implications of acquired *CDKN2A* deletions, GLASS patients with tumors carrying a high small deletion burden at recurrence (top tertile) had significantly shorter overall survival (Fig. 5a, $P = 3.4e-02$, log rank-test). The association remained significant when accounting for the small deletion burden as a continuous variable and possible confounding variables, indicating a robust correlation (Extended Data Fig. 5c, HR = 1.19 [95% CI: 1.01 – 1.14]; $P = 4.3e-02$, Wald test). Multivariable modeling using a limited subset of patients with detailed dosage information in the GLASS cohort ($n=21$) showed that the association between small deletion burden and survival is dose-independent ($P = 2e-02$). Separating the overall survival time into surgical interval and post-recurrence survival indicated that the association of high newly acquired small deletion burden with worse survival was limited to post-recurrence survival (Fig. 5a, $P = 3.4e-03$, log-rank test). Surgical interval times did not differ significantly between the three tertiles (Fig. 5a, $P = 5.6e-01$), suggesting that glioma patients may initially benefit equally from RT, but after exposure to RT and acquisition of the deletion signature, tumors may lose sensitivity to further radiotherapy. This pattern is reminiscent of the association between hypermutant glioma and temozolomide therapy²⁰.

In 958 RT-treated samples from the HMF cohort (Extended Data Fig. 1g), we also found that patients harboring a high small deletion burden (top tertile) had significantly shorter survival than other RT-treated cases (Fig. 5b, $P < 4e-04$, log rank-test). Similarly, stratifying HMF patients into tertiles by ID8 burden associated an intermediate or high ID8 burden with poor survival and a low ID8 burden with more favorable outcomes (Extended Data Fig. 5b). Therefore, the presence of a high number of RT-associated small deletions identifies a tumor that has initially responded to therapy, but which may have lost some or all of the treatment sensitivity. Combined, these results suggest that a higher deletion burden may reflect a scenario that is favorable to the tumor characterized by proficient DNA repair resulting in less tumor cell killing and decreased treatment efficacy.

DISCUSSION

Prior studies on radiation induced tumors have shown a range of genomic effects and have suggested the involvement of various DNA double strand break repair mechanisms^{30,32–35}. We identified a unique signature of RT-associated deletions carrying characteristics of DSB-repair by canonical non-homologous end joining. This work extends our knowledge on the genomic response to radiotherapy and provides direction for the development of effective radiosensitizers.

The significant expansion of clones harboring RT-associated genomic events depends on clonal selection or drift³⁶. Therefore, the increased small deletion burden in combination with poor outcomes may reflect the emergence of more competitive clones under RT-induced stress, innately active repair processes ensuring tumor maintenance, or a combination of these two. We found that a higher load of RT-associated deletions was linked to worse patient outcomes. Thus, additional rounds of RT in patients with recurrent or metastatic tumors containing a significant increase in small deletion burden is unlikely to further extend progression-free survival. The ability to effectively repair RT-induced damage implies that sensitivity to RT is intrinsically diminished or has progressively been lost due to for example clonal selection. Inhibiting these repair processes could potentially sensitize tumors to the tumor-killing effect of ionizing radiation. *CDKN2A* homozygous deletions were acquired in RT-treated IDH-mutant gliomas but not in untreated recurrent IDH-mutant gliomas, suggesting that radiotherapy-induced DNA damage promotes the acquisition of this poor prognostic marker, and implicating a convergence between RT-induced DSB repair and cell cycle checkpoints. A biomarker able to readily detect an increased small deletion burden may help reduce treatment costs and avoid RT-associated patient comorbidities and side-effects.

We note several limitations to our study. The HMF metastatic dataset comprises samples from a single time point, preventing the attribution of alterations as post-treatment. Furthermore, the treatment annotation in HMF does not precisely describe whether only the initial tumor or additionally the metastatic site were irradiated. Considering these caveats, the effects of RT described in this study might be more significant than what we have observed. Additionally, evolutionary pressures for local and distant metastases, which were analyzed homogeneously in this study, might be fundamentally different³⁷. RT may have no or a different impact on metastases that are not immediately within the field of the radiation, requiring further investigations in dedicated datasets.

Compounds that inhibit DNA repair may improve the response of cancer cells to radiotherapy. Numerous clinical and preclinical studies have shown efficacy in targeting DNA repair. Inhibitors directed at poly (ADP-ribose) polymerase (*PARP*) in homologous recombination-deficient tumors (synthetic lethality) were shown to be effective in the treatment of various cancer types^{38–40}. Effective inhibitors of NHEJ have not yet been reported but may sensitize tumors to radiotherapy. Inhibitors of ATM serine/threonine kinase (ATM), a protein kinase that activates DSB repair; and DNA-dependent protein kinase catalytic subunit (DNA-PKc), a kinase that catalyzes repair at the DSB locus, were shown to be effective in pre-clinical studies and phase I trials of diffuse glioma^{41–44}. The

identification of enrichment of APOBEC associated mutational signatures may warrant further evaluation of targeting cytosine deaminases for cancer therapy⁴⁵. The present study highlights the importance of effective DNA repair in therapy resistance.

MATERIALS AND METHODS

Patient cohort

We curated a cohort of 190 patients with high-quality longitudinal DNA sequencing data, including treatment naïve primary and matched post-treatment first recurrence tumor samples from the GLASS dataset⁵. We classified paired samples according to the 2016 World Health Organization (WHO) classification into three subtypes: *IDH* mutant with 1p/19q co-deletion (*IDH*mut-codel), *IDH* mutant without 1p/19q co-deletion (*IDH*mut-noncodel) and *IDH* wild type (*IDH*wt)¹¹. The GLASS cohort used in this manuscript consists of $n = 106$ whole genome sequencing samples ($n = 53$ primary samples, $n = 53$ matched first recurrence samples) and $n = 274$ whole exome sequencing (WES) samples ($n = 106$ primary samples, $n = 106$ matched first recurrence samples). Detailed information on sequence platforms, capture kits and read length information are outlined in the GLASS marker paper⁵.

For validation analyses, we curated a metastatic cohort from the Hartwig Medical Foundation (HMF) comprising a total of 4549 samples⁸. The HMF cohort consists of metastatic tumor samples that were collected following local or systemic treatment as part of the CPCT-02 (NCT01855477) and DRUP (NCT02925234) clinical trials. Biopsy samples from a wide range of tumor types collected at various hospitals across the Netherlands were sequenced at the core facilities of the Hartwig Medical Foundation. Whole genome sequencing was performed for each sample according to standardized protocols⁴⁶. Detailed information on sequence platforms, capture kits and read length information are outlined in the HMF marker paper⁸. VCF files with mutations and associated metadata were downloaded from The Hartwig Medical Database (<https://database.hartwigmedicalfoundation.nl>). After application of filtering criteria using BCFTools 1.9 (as described in detail in Extended Data Fig. 1e) a set of $n = 3693$ were defined and used for the majority of analyses throughout the manuscript. For survival analyses we selected RT-treated samples with sufficient survival information ($n = 958$). All prior radiotherapy data were extracted using clinical data as present in the CPCT-02 eCRF on December 08, 2020. These data were not cleaned and represent the data entered by the clinical sites. The prior radiotherapy was categorized as curative intent, palliative intent or other. All other instances were manually curated by the principal investigator. All adjuvant / neo-adjuvant or post-operative radiotherapy was considered curative intent radiotherapy. All local radiotherapy for pain relief or other symptom-directed goals were considered as palliative. Some items were not specified, and those events were not included in our analysis. We also excluded all radiotherapy for non-malignant disease states, specifically for gynecomastia treatment after castration. We cannot exclude over- or underrepresentation of the radiation signatures as we are unaware whether the metastases that were biopsied were not already present at the time of radiotherapy.

Variant Calling

Variant calling in the GLASS dataset was performed according to the GATK Best practices using GATK 4.1.0.0 and publicly released as part of a previous publication⁵. Briefly, GATK 4.1. was used for variant calling in tumor samples against a matched normal control. Additionally, panels of normals were constructed across multiple control samples from the same tissue source and sequencing center. Variants were broadly filtered for germline variants, cross-sample contamination, read orientation and sequence context. Variants were called across all samples for a given patient. Variants with a minimum coverage of 10 reads in both primary and recurrence and a minimum VAF of 10% for either the primary or the recurrence were included for further analysis. Variants were considered to be present if at least one mutant read was detected in a sample. Mutations directly overlapping with known repeat regions according to the repeatmasker database were removed. Specifically, we filtered out all variants in known repeat regions, including DNA satellites, microsatellites, long terminal repeats, transposable elements (LINE/SINE elements) and low complexity regions. Variant clonality was inferred for each patient individually using PyClone (v.0.13.1) and as described in more detail in the GLASS marker paper.

Mutation burden comparison

The mutation burden was calculated as the number of mutations per megabase (Mb) with at least 10x coverage and stratified by variant type. The overall tumor mutation burden (TMB) was calculated as the sum of the burden of small deletions, small insertions and single nucleotide variants. Recurrent tumors with greater than 10 mutations per Mb were considered hypermutated as previously described⁵. For the comparison of mutation burden between RT-treatment groups in the GLASS dataset, we calculated the burden of mutations unique to the recurrent tumors and therefore were acquired after treatment. To adjust for confounding covariables, we fitted a multivariable log-linear regression model using the *glm* function in R. In addition to RT-treatment, we included TMZ-treatment, hypermutation, surgical interval in months and molecular subtype as variables. The small deletion burden in the GLASS dataset was not confounded by batch effects. Accordingly, we included the full therapy and tumor type information for mutation burden analyses in the Hartwig metastatic cohort. To adjust for negative infinite values resulting from the log-transformation in the GLASS cohort, we added a constant value of 1 to the log function. For the metastatic cohort, the log-transformation did not result in (negative) infinite values and therefore not necessitating the addition of a constant value.

Association of deletions with non-B DNA structures

The genomic locations of non-canonical DNA structures were derived from the Non-B DNA database⁴⁷. We calculated for every variant position and, for comparison, for 250,000 randomly sampled positions from the reference genome, the distance to non-B features as a continuous (absolute distance to genomic feature in bp) or categorical (position in or up to 100 bp to genomic feature – yes/no) values. We used a two-sided Mann-Whitney *U* test for differences in the genomic properties of variants in radiation-induced and non-radiation-induced tumors after adjusting for random background distribution.

dNdScv

For quantification of selection processes at the level of individual genes dependent on radiation therapy, we calculated dN/dS ratios as previously described⁵. Briefly, the R package dNdScv¹⁷ was run using the default and recommended parameters for each mutational fraction (private to primary, shared between primary and recurrence and private to recurrence). All analyses were conducted separately within radiotherapy-naïve and radiotherapy-treated groups.

Sequence microhomology

Sequence microhomology was determined by iteratively comparing the 3' end of the deleted sequence to the 5' flanking sequence. Any deletion demonstrating at least 2nt of homology was considered microhomology-mediated. The homologous sequence was characterized and further analyzed for the presence of 1nt, 2nt and 3nt repeats. The repeat unit and number of repeats were quantified.

Mutational signatures

SigProfiler was used to extract and plot mutational signatures of single base substitutions (SBS), double base substitutions (DBS) and indels (ID)¹⁸. Absolute and relative contributions of signatures were determined using modified functions from the MutationalPatterns R package⁴⁸. Briefly, we fitted the mutational profile matrix generated with SigProfiler to the catalog of previously identified COSMIC mutational signatures (v3, May 2019) by solving the non-negative least squares problem. The single base substitution signatures SBS31 and SBS35 have been previously linked to platinum therapy^{14,18}. Analysis of the HMF cohort using the signatures we extracted confirmed these previously established associations, providing further credence to the identified signatures. SigProfilerPlotting⁴⁹ was used to visualize the distribution of indel characteristics (Extended Data Fig. 3a–d).

Structural variants

For the GLASS dataset split reads and discordant read pairs were extracted from all tumor and normal BAM files using samtools 1.7⁵⁰. We used the *lumpyexpress* tool (from LUMPY 0.2.13) to call structural variants providing the data associated with the set of normal and tumor samples belonging to one patient⁵¹. CNV predictions inferred from read-depth using CNVnator 0.3.3 were additionally provided to garner further support for identified variants⁵². The resulting call set was post-processed using SVtyper 0.6.0 to genotype structural variants for each individual sample belonging to a patient⁵³. Finally, we used GATK VariantFiltration to filter all variants with less than four reads of support and those with quality scores less than ten⁵⁴. Variants that showed any support in non-tumor samples were additionally removed. Variants were quantified per sample and further stratified according to type (translocation, duplication, deletion and inversion). We computed the change in frequencies for each patient by dividing the rate at recurrence by the rate at primary. Only variants spanning at least 20bp were considered.

Microsatellite Instability and Homologous Recombination Deficiency

Microsatellite instability (MSI) and homologous recombination deficiency (HRD) status were assigned according to previously defined criteria¹³. In short, MSI was determined in samples with >14000 indel repeats; HRD was classified based on a probability score of ≥ 0.5 according to the CHORD (Classifier of Homologous Recombination Deficiency) algorithm.

Aneuploidy calculation

Arm-level aneuploidy data from the GLASS dataset was obtained from a previous publication and copy number segmentation files from HMF were processed into arm-level copy number calls using the same methods⁵. Chromosomes demonstrating euploidy in both arms were considered euploid. Chromosomes with equidirectional aneuploidy in both arms or aneuploidy in a single arm and indeterminate ploidy in the other arm were considered “simple aneuploid”. Chromosomes with aneuploidy in one arm and incongruent ploidy in the other arm were considered “complex aneuploid”. Aneuploidy events were quantified for each tumor sample.

Statistical methods

All data analyses were conducted in R 3.6.1 (broadly using tidyverse 1.3.0), Python 3.7.3 and PostgreSQL 10.5. R was interfaced with the PostgreSQL database used for data storage using the unixODBC 2.3.6 driver plus DBI 1.0.0 and odbc 1.1.6 R packages. All survival analyses including Kaplan–Meier plots and Cox proportional hazards models were conducted using the R packages *survival* and *survminer*. For unpaired group comparisons the two-sided Mann-Whitney *U* test and two-sided Kruskal-Wallis test were used and for paired longitudinal comparisons the two-sided Wilcoxon signed-rank test was applied. Forest plots were generated using the R package *forestmodel*. Survival times for the GLASS dataset were calculated as described previously⁵. In the HMF metastatic cohort, we calculated survival starting from the date of biopsy to date of death. For patients that were alive, we used the last date of follow-up (date of treatment end) as censoring.


Data availability

Processed sequencing data from the GLASS project used in this study are available on Synapse, at <https://www.synapse.org/glass>. The WGS, RNA-seq, and corresponding clinical data used in this study were made available by the Hartwig Medical Foundation and were accessed under a license agreement (HMF DR-057 version 3.0). Data access can be obtained by filling out a data request forms. The form and detailed application procedures can be found online at <https://www.hartwigmedicalfoundation.nl/applying-for-data/>. The repeatmasker database used in this manuscript is available online at <https://www.repeatmasker.org/>.

Code availability

Pipeline scripts can be found at <https://github.com/fpbarthel/GLASS>. Custom scripts for analyses performed in this manuscript can be found at <https://github.com/EmreKocakavuk/RTscars>.

Extended Data



Extended Data Fig. 1. Radiotherapy specifically drives small deletion burden independent of multiple variables

a. Boxplot (in this and all following figures: boxes span quartiles, center lines as medians, whiskers represent absolute range, excluding outliers): burden of post treatment mutations (mutations/mb) in RT-naïve (n=34) and RT-received (n=156) patients from GLASS cohort. Mutations separated by DEL (deletions), INS (insertions) and SNV (single nucleotide variants). Two-sided Mann-Whitney *U* test.


b. Acquired small deletion burden comparison between RT-naïve and RT-received cases separated by molecular subtype. Two-sided Mann Whitney U test.

c. Comparison of mean cancer cell fraction of small deletions per patient in GLASS separated by P, primary-only fraction, S, shared fraction and R, recurrence-only fraction and by HM, hypermutation. Two-sided Mann-Whitney *U* test.

d. Forest plots: multivariable log-linear regression model of acquired mutation burden (mutations/mb) in GLASS. Point, mean estimate; lines, 95%-confidence-interval. Two-sided t-test (**=p<0.01, ***=p<0.001).

e. Sample selection and filtering criteria for HMF including a detailed description of the usage for specific figures.

- f. Separation of lung, breast and bone/soft tissue cancers into respective subtypes. Comparison of small deletion burden between RT-, RT+pal and RT+cur samples. Two-sided Kruskal-Wallis test.
- g. Boxplots depicting burden of small deletions in HRD-/MSI- (n=3,413), HRD+ (n=218) and MSI+ (n=62) samples from the HMF cohort separated by RT-status. Two-sided Mann-Whitney *U* test.
- h. Forest plots depicting multivariable log-linear regression model for mutation burdens in HMF. Two-sided t-test. Mutations separated into small deletions/insertions and SNVs. Independent variables: age, primary tumor location, DNA repair deficiency background and treatment including radiotherapy, taxane, alkylating agents, platin and others.
- i. Comparison of small deletion counts between control vs ionizing radiation groups (PMID:30982602). Two-sided Mann-Whitney *U* test.
- k. Distribution of small deletion counts per treatment group (PMID:30982602). Data presented as mean values $\pm$ standard error of the mean, and red dots indicate median count of small deletions.



Extended Data Fig. 2. Genomic characteristics of RT-associated small deletions


- a. Comparison of mean deletion lengths of acquired deletions in RT- vs RT+ *IDHmut* gliomas. Two-sided Mann-Whitney *U* test.
- b. Metastatic cohort: Boxplots depicting mean deletion lengths in RT-naïve (left) and palliative RT-treated (middle) and curative RT-treated (right) tumor samples separated by primary tumor location. Two-sided Kruskal-Wallis test.

c. Longitudinal comparison (X-Axis) of mean distances of deletions to non-B DNA features in kb (Y-Axis) in *IDH*mut glioma cases. Cases separated by radiation treatment and hypermutation. Note that neither in hypermutated nor in RT-naïve non-hypermutated glioma samples significant longitudinal differences were observed. Two-sided paired Wilcoxon signed-rank test.

d. Gene-wise dN/dS estimates by RT (rows) and fraction (columns) in GLASS. Two-sided likelihood ratio tests. Genes sorted by Q-value (Bonferroni-adjusted P-value) and P-value. Q-values indicated in color, whereas P-values shown in light grey. Q-value threshold of 0.05 indicated by a horizontal red line.

e. Comparison of proportion of deletions for *IDH*mut glioma samples separated by RT and hypermutation. Two-sided paired Wilcoxon signed-rank test. For each sample, the proportion of deletions with 1bp length, > 1bp length with microhomology and > 1bp length without microhomology add up to 1. Bottom right panels (RT-received non-hypermutators) presented in Figure 2d and shown here for comparison with other groups.

f. Comparison of proportion of deletions in metastatic cohort between RT-treated and RT-naïve cases using two-sided Kruskal-Wallis test. In bone/soft tissue, breast and head & neck and nervous system cancers, significantly lower proportions of deletions >1bp with microhomology were observed in RT-treated samples compared to RT-naïve samples. In contrast, RT-received breast, colon/rectum, esophagus, nervous system and prostate tumor samples showed significantly higher proportions in deletions > 1bp without microhomology. Boxes span quartiles, center lines as medians, whiskers represent absolute range, excluding outliers.




Extended Data Fig. 3. Mutational signatures associated with RT

a-d. Distribution of indel types for post-treatment mutations in the GLASS cohort, separated by RT (a, c, RT- negative; b, d, RT-treated) and HM (a-b, Hypermutator; c-d, Non-Hypermutator). Note that patterns of indels in hypermutated samples resemble the previously identified MSI signature ID2, whereas RT-treated Non-Hypermutant gliomas harbor large similarities with ID8. Sample sizes for each subgroup are annotated.

e. Comprehensive comparison of all 17 COSMIC indel (ID) signatures in *IDH*mut glioma. Top 2 panels display longitudinal comparison of absolute signature contributions separated by radiation treatment (RT+ and RT-). Middle 2 panels display longitudinal comparison of relative signature contributions separated by radiation treatment. For these panels two-sided Mann-Whitney U test was applied for statistical testing. (ns = not significant, * = $p < 0.05$,

** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$). Note that ID8 is the only signature consistently associated with radiation therapy across different comparisons, nominating it as a robust signature of radiotherapy. Boxes span quartiles, center lines as medians, whiskers represent absolute range, excluding outliers.

f. Absolute (top) and relative (bottom) contribution of ID8 signature in metastatic cohort compared between cases with prior radiation treatment and cases without prior radiation treatment separated by tumor types. Note that most tumor types show significantly higher values of the signature in curative RT+ cases. Two-sided Kruskal-Wallis test was applied for statistical testing. Boxes span quartiles, center lines as medians, whiskers represent absolute range, excluding outliers.




Extended Data Fig. 4. Effects of radiotherapy on structural variants

a. Analysis of structural variants (SVs) in glioma samples (Translocations, Duplications, Deletions, Inversions). For each patient, number of SVs were calculated pre-and post-treatment and the proportional increase after therapy for each SV-type was plotted separately for RT-naïve and RT-treated samples. Based on the distribution of proportional increase from primary to recurrence, a cutoff was defined for $> 50\%$ increase that was further used for analyses in Figure 4a.

b. To support analyses presented in Figure 4a, a multivariable logistic regression model was fitted for the $> 50\%$ increase values of the structural variant types. Two-sided Wald test. This model includes radiation therapy, temozolomide therapy, molecular subtype and surgical interval as variables.

- c. Schematic overview of separation of aneuploidy events into whole chromosome aneuploidy as a result of simple segregation errors and partial aneuploidy as a result of complex segregation errors.
- d. Longitudinal analysis of partial aneuploidy in *IDH*mut glioma samples. Dots are proportional to the frequency of whole chromosome loss integer for each subgroup. Two-sided paired Wilcoxon rank-signed test.
- e. Multivariable Poisson regression model for whole chromosome losses in *IDH*mut glioma including molecular subtype, RT, TMZ, surgical interval and *CDKN2A* status at recurrence as variables. Two-sided Wald test. Note that *CDKN2A* homdel, but not RT is independently associated with higher whole chromosome losses.
- f. Density plots over integers of whole chromosome deletion scores for comparison between primary vs recurrent glioma samples, separated by radiotherapy.
- g. Density plots over integers of whole chromosome deletion scores for comparison between RT-naïve vs RT+pal vs RT+cur and/or *CDKN2A* homdel vs. wild-type (WT) samples from the HMF dataset. Note that *CDKN2A* homdel is associated with higher whole chromosome deletion scores, independent of RT. Within samples with *CDKN2A* homdel, samples that were RT-treated with curative intent show the highest deletion scores.



Extended Data Fig. 5. Radiotherapy-associated genomic scars linked to poor survival

a. Left: Kaplan-Meier survival plot comparing overall survival time dependent on *CDKN2A* status at recurrence using two-sided log-rank test in *IDH* mutant glioma samples. Right: Multivariable cox regression model including *CDKN2A* status at recurrence, TMZ-treatment, molecular subtype and Age as variables. Two-sided Wald test was applied.

b. Left: Kaplan-Meier survival plot comparing survival time dependent on *CDKN2A* status at metastasis using two-sided log-rank test RT-treated metastases (n = 958 with available survival information). Middle: Kaplan-Meier survival plot comparing survival time dependent on aneuploidy burden at metastasis using two-sided log-rank test in RT-treated metastases (n = 958 with available survival information). Samples were separated into 3 tertiles based on whole chromosome loss aneuploidy scores: high (top tertile), intermediate (middle tertile) and low (bottom tertile). Right: Kaplan-Meier survival plot comparing survival time dependent RT signature ID8 burden at metastasis using two-sided log-rank test in RT-treated metastases (n = 958 with available survival information). Samples were separated into 3 tertiles based on ID8 burden: high (top tertile), intermediate (middle tertile) and low (bottom tertile).

and low (bottom tertile). Note that a low ID8 burden is associated with better survival, indicating a better response to RT.

c. Multivariable cox regression model including deletion burden at recurrence as continuous variable, *CDKN2A* homozygous deletion, Temozolomide-treatment, molecular subtype and age as variables in RT-treated *IDH* mutant samples.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) have made available to the study.

This work was supported by the following NIH grants: R01 CA190121, R01 CA237208, R21 NS114873 and Cancer Center Support Grant P30 CA034196, grants from the Musella Foundation, the B*CURED Foundation, the Brain Tumour Charity, and the Department of Defense W81XWH1910246 (R.G.W.V).

F.P.B. is supported by the JAX Scholar program and the National Cancer Institute (K99 CA226387). F.S.V. is supported by a postdoctoral fellowship from The Jane Coffin Childs Memorial Fund for Medical Research. K.C.J. is the recipient of an American Cancer Society Fellowship (130984-PF-17-141-01-DMC). E.K. is recipient of an MD-Fellowship by the Boehringer Ingelheim Fonds and is supported by the German National Academic Foundation.

REFERENCES

1. Barton MB et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. *Radiother Oncol* 112, 140–4 (2014). [PubMed: 24833561]
2. Tyldesley S et al. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. *Int J Radiat Oncol Biol Phys* 79, 1507–15 (2011). [PubMed: 20605338]
3. Chang HHY, Pannunzio NR, Adachi N & Lieber MR Non-homologous DNA end joining and alternative pathways to double-strand break repair. *Nat Rev Mol Cell Biol* 18, 495–506 (2017). [PubMed: 28512351]
4. Campbell BB et al. Comprehensive Analysis of Hypermutation in Human Cancer. *Cell* 171, 1042–1056 e10 (2017). [PubMed: 29056344]
5. Barthel FP et al. Longitudinal molecular trajectories of diffuse glioma in adults. *Nature* 576, 112–120 (2019). [PubMed: 31748746]
6. Touat M et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature* 580, 517–523 (2020). [PubMed: 32322066]
7. Behjati S et al. Mutational signatures of ionizing radiation in second malignancies. *Nat Commun* 7, 12605 (2016). [PubMed: 27615322]
8. Priestley P et al. Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature* 575, 210–216 (2019). [PubMed: 31645765]
9. Consortium GG. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. *Neuro Oncol* 20, 873–884 (2018). [PubMed: 29432615]
10. Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352, 987–96 (2005). [PubMed: 15758009]
11. Louis DN et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 131, 803–20 (2016). [PubMed: 27157931]
12. Lutz ST, Jones J & Chow E Role of radiation therapy in palliative care of the patient with cancer. *J Clin Oncol* 32, 2913–9 (2014). [PubMed: 25113773]

13. Nguyen L, J WMM, Van Hoeck A & Cuppen E Pan-cancer landscape of homologous recombination deficiency. *Nat Commun* 11, 5584 (2020). [PubMed: 33149131]
14. Pich O et al. The mutational footprints of cancer therapies. *Nat Genet* 51, 1732–1740 (2019). [PubMed: 31740835]
15. Kucab JE et al. A Compendium of Mutational Signatures of Environmental Agents. *Cell* 177, 821–836.e16 (2019). [PubMed: 30982602]
16. Georgakopoulos-Soares I, Morganella S, Jain N, Hemberg M & Nik-Zainal S Noncanonical secondary structures arising from non-B DNA motifs are determinants of mutagenesis. *Genome research* 28, 1264–1271 (2018). [PubMed: 30104284]
17. Martincorena I et al. Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell* 171, 1029–1041.e21 (2017). [PubMed: 29056346]
18. Alexandrov LB et al. The repertoire of mutational signatures in human cancer. *Nature* 578, 94–101 (2020). [PubMed: 32025018]
19. Davies H et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nat Med* 23, 517–525 (2017). [PubMed: 28288110]
20. Touat M et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature* 580, 517–523 (2020). [PubMed: 32322066]
21. Nik-Zainal S et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* 534, 47–54 (2016). [PubMed: 27135926]
22. Roberts SA et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nat Genet* 45, 970–6 (2013). [PubMed: 23852170]
23. Lei L et al. APOBEC3 induces mutations during repair of CRISPR-Cas9-generated DNA breaks. *Nat Struct Mol Biol* 25, 45–52 (2018). [PubMed: 29323274]
24. Nowarski R & Kotler M APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion. *Cancer Res* 73, 3494–8 (2013). [PubMed: 23598277]
25. Nowarski R et al. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. *Blood* 120, 366–75 (2012). [PubMed: 22645179]
26. Volkova NV et al. Mutational signatures are jointly shaped by DNA damage and repair. *Nat Commun* 11, 2169 (2020). [PubMed: 32358516]
27. Ceccarelli M et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell* 164, 550–563 (2016). [PubMed: 26824661]
28. Adewoye AB, Lindsay SJ, Dubrova YE & Hurles ME The genome-wide effects of ionizing radiation on mutation induction in the mammalian germline. *Nature communications* 6, 6684–6684 (2015).
29. Bakhoun SF et al. Numerical chromosomal instability mediates susceptibility to radiation treatment. *Nature communications* 6, 5990–5990 (2015).
30. Rose Li Y et al. Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice. *Nat Commun* 11, 394 (2020). [PubMed: 31959748]
31. Touil N, Elhajouji A, Thierens H & Kirsch-Volders M Analysis of chromosome loss and chromosome segregation in cytokinesis-blocked human lymphocytes: non-disjunction is the prevalent mistake in chromosome segregation produced by low dose exposure to ionizing radiation. *Mutagenesis* 15, 1–7 (2000). [PubMed: 10640524]
32. Behjati S et al. Mutational signatures of ionizing radiation in second malignancies. *Nat Commun* 7, 12605 (2016). [PubMed: 27615322]
33. Davidson PR, Sherborne AL, Taylor B, Nakamura AO & Nakamura JL A pooled mutational analysis identifies ionizing radiation-associated mutational signatures conserved between mouse and human malignancies. *Sci Rep* 7, 7645 (2017). [PubMed: 28794481]
34. Lopez GY et al. The genetic landscape of gliomas arising after therapeutic radiation. *Acta Neuropathol* 137, 139–150 (2019). [PubMed: 30196423]
35. Phi JH et al. Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas. *Acta Neuropathol* 135, 939–953 (2018). [PubMed: 29644394]
36. Hu Z et al. Quantitative evidence for early metastatic seeding in colorectal cancer. *Nat Genet* 51, 1113–1122 (2019). [PubMed: 31209394]

37. Reiter JGet al.Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. *Nat Genet*52, 692–700 (2020). [PubMed: 32451459]
38. Wiggans AJ, Cass GK, Bryant A, Lawrie TA & Morrison J Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. *Cochrane Database Syst Rev*, CD007929 (2015).
39. Su JMet al.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. *Neuro Oncol*16, 1661–8 (2014). [PubMed: 24908656]
40. O’Neil NJ, Bailey ML & Hieter P Synthetic lethality and cancer. *Nature reviews. Genetics* 18, 613–623 (2017).
41. Munster Pet al.First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. *Cancer Manag Res*11, 10463–10476 (2019). [PubMed: 31853198]
42. Goldberg FWet al.The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-p yran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. *J Med Chem* (2020).
43. Thijssen Ret al.Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. *Blood*128, 574–83 (2016). [PubMed: 27235137]
44. Timme CR, Rath BH, O’Neill JW, Camphausen K & Tofilon PJ The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts. *Mol Cancer Ther* 17, 1207–1216 (2018). [PubMed: 29549168]
45. Li Met al.First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. *ACS Chem Biol*7, 506–17 (2012). [PubMed: 22181350]
46. Bins Set al.Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. *Oncologist*22, 33–40 (2017). [PubMed: 27662884]
47. Cer RZet al.Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools. *Nucleic acids research*41, D94–D100 (2013). [PubMed: 23125372]
48. Blokzijl F, Janssen R, van Boxtel R & Cuppen E MutationalPatterns: comprehensive genome-wide analysis of mutational processes. *Genome medicine* 10, 33–33 (2018). [PubMed: 29695279]
49. Bergstrom ENet al.SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. *BMC Genomics*20, 685 (2019). [PubMed: 31470794]
50. Li Het al.The Sequence Alignment/Map format and SAMtools. *Bioinformatics*25, 2078–9 (2009). [PubMed: 19505943]
51. Layer RM, Chiang C, Quinlan AR & Hall IM LUMPY: a probabilistic framework for structural variant discovery. *Genome Biol* 15, R84 (2014). [PubMed: 24970577]
52. Abyzov A, Urban AE, Snyder M & Gerstein M CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. *Genome Res* 21, 974–84 (2011). [PubMed: 21324876]
53. Chiang Cet al.SpeedSeq: ultra-fast personal genome analysis and interpretation. *Nat Methods*12, 966–8 (2015). [PubMed: 26258291]
54. Van der Auwera GAet al.From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics*43, 11 10 1–11 10 33 (2013). [PubMed: 25431634]




Fig. 1. Radiotherapy is associated with an increased small deletion burden

a. Boxplot (in this and all following figures: boxes span quartiles, center lines as medians, whiskers represent absolute range, excluding outliers) depicting the burden of newly acquired/post-treatment small deletions (deletions/Mb) in RT-naïve (n = 34) and RT-received (n = 156) patients from the GLASS cohort. Two-sided Mann-Whitney U test was applied for statistical testing.

b. Longitudinal comparison of small deletion burden between primary and recurrent glioma samples, separated by hypermutation (HM) and Radiotherapy (RT). Two-sided paired Wilcoxon signed-rank test was applied for statistical testing

c. Forest plot showing multivariable log-linear regression model of newly acquired small deletion burden(deletions/Mb) including 1. TMZ-treatment, 2. Hypermutation, 3. RT-

treatment, 4. Molecular subtype and 5. Surgical interval (in months) as variables. Two-sided t-test was applied. OR, Odds Ratio, CI, confidence interval.

d. Top. Metastatic cohort: Boxplots depicting small deletion burden (deletions/Mb) in RT-naïve (left), RT-treated with palliative intent (RT+ pal, middle) and RT-treated with curative intent (RT+ cur, right) tumor samples separated by primary tumor location. Two-sided Kruskal-Wallis test was applied for statistical testing. **Bottom.** Sample sizes of metastatic cohort separated by primary tumor location.




Fig. 2. Radiotherapy-associated small deletions harbor a characteristic genomic signature

a. Length distribution in GLASS. Left: Mean deletion lengths in primary vs recurrent *IDH* mutant glioma (n=81), separated by RT-treatment (RT+, n=32, RT-, n=49). Two-sided paired Wilcoxon signed-rank test. **Right:** Y-Axis, proportion of deletions; X-Axis, deletion length >1bp. Proportions calculated for each patient, mean (point) and 95%-CI (line-range) compared longitudinally in RT-treated non-hypermutable glioma (n=44). Two-sided paired Wilcoxon signed-rank test (*=p<0.05, **=p<0.01).

Shaded area (5–15 bp): size range for which the most apparent differences were observed.

b. Length distribution in HMF. Left: Comparison of mean deletion lengths in RT-naïve vs RT+pal vs. RT+cur samples. Two-sided Kruskal-Wallis test. **Right:** Y-Axis, proportion of deletions; X-Axis, deletion length >1bp. Proportions calculated for each patient, mean (point) and 95%-CI (line-range) compared between RT-naïve vs. RT+pal vs. RT+cur samples. Two-sided Kruskal-Wallis test (*= $p < 0.05$, **= $p < 0.01$, ***= $p < 0.001$, ****= $p < 0.0001$).

c. Relation to genomic features in GLASS. Left: Distribution of deletions in relation to genomic features. Y-Axis: non-B DNA genomic feature, X-Axis: Log10-ratio of mean distance of non-radiation-associated and radiation-associated post-treatment deletions to genomic feature over background distribution in non-hypermuted glioma samples (n=69). Distribution of radiation-associated deletions shows little variability (narrow 95%-CI) and resemble background distribution more closely (closer to 0). Two-sided Mann-Whitney *U* test. **Right:** Empirical cumulative distribution function (ECDF, Y-Axis) of distance to non-B DNA features in kb (X-Axis) post-radiated non-hypermuted recurrent samples (n=44). Neither in hypermutated, nor in RT-naïve non-hypermuted gliomas longitudinal differences were observed (Extended Data Fig. 2c).

d. Small deletion categories in GLASS. Left: Separation of small deletions in the GLASS cohort into 3 major categories: 1bp (gray), >1bp without microhomology (purple) and >1bp with microhomology (orange) in *IDH* mutant gliomas (n=81). Microhomology category further classified based on the occurrence of microhomology repeat sequences and length of repeats.

Right: Comparison of proportion of deletions for each RT-treated non-hypermuted glioma sample (n=44, further comparisons in Extended Data Fig. 2e) using two-sided paired Wilcoxon signed-rank test.




Fig. 3. ID8 and APOBEC-SBS signatures associated with radiotherapy.

Indel (ID) and single base substitution (SBS) mutational signatures in the GLASS and HMF cohorts associated with RT (radiotherapy), Hypermutation (HM), Microsatellite instability (MSI) and homologous recombination deficiency (HRD). RT+, mean contribution = 0.22, vs. RT-, mean contribution, $P = 7.4\text{e-}05$, $Q = 3.8\text{e-}03$, two-sided Mann-Whitney U test and false discovery rate, respectively. Bars in the petal plots not reaching statistical significance (defined as $\text{FDR} < 0.01$) are indicated in grey.




Fig. 4. RT is associated with aneuploidy and larger deletions

a. RT-associated increase in large deletions and inversions. Analysis of structural variants (SVs) after RT in *IDH*mut glioma samples with sufficient quality for calling ($n = 70$): Translocations, Duplications, Deletions, Inversions. For each patient, number of SVs were calculated pre-and post-treatment. Based on the distribution of percent increase from primary to recurrence, cutoff was set for $> 50\%$ increase (Extended Data Fig. 4a). Comparison of proportion of samples with/without increase of given SVs between RT-treated vs RT-naïve. Two-sided Fisher's exact test.

b. RT-associated *CDKN2A* homozygous deletions. Depicted are proportions of *IDH*mut glioma samples ($n = 81$) harboring a homozygous deletion in *CDKN2A*. Using two-sided Fisher's exact test, proportions were compared between RT-received recurrence (RT+) vs. RT-naïve recurrence (RT-) vs. samples prior to treatment (Primary). Detailed distributions of whole chromosome deletion scores provided in Extended Data Fig. 4f.

c. RT-associated whole chromosome aneuploidy. Upper: Longitudinal comparison of whole chromosome aneuploidy scores separated by RT-treatment for *IDH*mut glioma samples with sufficient quality for calling and complete treatment annotation (total $n = 69$, RT-treated $n = 42$, RT-naïve $n = 27$). **Bottom:** Separation of whole chromosome aneuploidy into whole chromosome gain (left) and whole chromosome loss (right) scores, respectively. Dots are proportional to the frequency of whole chromosome loss integer for each subgroup. Two-sided paired Wilcoxon rank-signed test.

d. Validation of SV and aneuploidy results in HMF. Upper: Comparison of whole chromosome deletion scores between RT-naïve vs RT+pal vs RT+cur and/or *CDKN2A* homdel vs. WT samples. Note that *CDKN2A* homdel is associated with higher whole chromosome deletion scores, independent of RT. Within samples with *CDKN2A* homdel, samples that were RT-treated with curative intent show the highest deletion scores. Dots are proportional to the frequency of whole chromosome loss integer for each subgroup. Two-sided Kruskal-Wallis test. Detailed distributions of whole chromosome deletion scores provided in Extended Data Fig. 4g. **Bottom:** Multivariable poisson regression model for whole chromosome deletion scores integrating RT, *CDKN2A* and tumor types as variables. Two-sided Wald-test was applied.




Fig. 5. RT-associated genomic changes are linked to poor survival

a. Association of RT-related deletions with survival in GLASS. **Left:** Kaplan-Meier survival plots comparing overall survival dependent on deletion burden at recurrence using log-rank test in RT-treated *IDH* mutant glioma samples ($n = 49$ with available survival information). Samples were separated into 3 tertile based on deletion burden at recurrence: High (top tertile), Intermediate (middle tertile) and Low (bottom tertile). Dotted lines indicate median overall survival times. Note the stepwise association of tertiles with survival. **Middle:** Kaplan-Meier survival plots comparing surgical interval/time to second surgery dependent on deletion burden at recurrence using two-sided log-rank test. **Right:** Kaplan-Meier survival plots comparing post-recurrence survival dependent on deletion burden at recurrence using two-sided log-rank test.

Fig. 5b Association of RT-related deletions with survival in HMF. Kaplan-Meier survival plots comparing survival time dependent on deletion burden at metastasis using two-sided log-rank test in RT-treated metastases ($n = 958$ with available survival information). Samples were separated into 3 tertiles based on deletion burden: High (top tertile), Intermediate

(middle tertile) and Low (bottom tertile). Dotted lines indicate median survival times. Note the stepwise association of tertiles with survival.